GLP-1 drugs: a new weekly shot cut body weight by about 18% in a trial
☕ Includes a question for the family ↓
GLP-1 drugs (Ozempic, Wegovy, Mounjaro)Part of a story we are following · 8 articles · See every update
If you have been watching the new weight-loss medicines, here is encouraging news: another one is joining the field, and it did very well in a large trial. A weekly shot that works like GLP-1 drugs helped adults lose a big share of their body weight.
In a study of 567 adults with overweight or obesity and no diabetes, people who took a once-weekly shot called ribupatide for 48 weeks lost about 16% to 18% of their body weight at the two higher doses, compared with about 1% for people who took a placebo. Ribupatide works on two of the body’s hunger and fullness signals, GLP-1 and a partner signal called GIP.
How the study worked
Researchers ran a randomized, double-blind, placebo-controlled trial at 55 sites in China. That means chance decided who got the medicine and who got a look-alike with no medicine, and neither the volunteers nor the staff knew who got which. All 567 adults also received lifestyle guidance. They were followed for 48 weeks, and the results were published in JAMA on November 15, 2026. The volunteers lived in China and were fairly young, so the results may look different in other groups.
What did the trial find?
The weight loss was large, and it grew with the dose. The study tested three doses: 2 mg, 4 mg and 6 mg. Here is the average change in body weight after 48 weeks.
| Group | Average weight change |
|---|---|
| Placebo | down 1.4% |
| Ribupatide 2 mg | down 10.7% |
| Ribupatide 4 mg | down 16.4% |
| Ribupatide 6 mg | down 17.7% |
The volunteers had an average age of 34.4 years. A loss of about 17% is a major change for a typical volunteer.
After taking the placebo effect out, the 6 mg group still came out ahead by 16.3 percentage points. The 4 mg group came out ahead by 15.0 points, and the 2 mg group by 9.3 points.
The study also counted how many people lost at least 5% of their body weight, a level doctors often use as a sign of real benefit. Here is how it played out:
- With the 4 mg dose, 88.0% of people reached it (124 of 141).
- With the 6 mg dose, 85.7% reached it (121 of 141).
- With the 2 mg dose, 68.1% reached it (97 of 142).
- With placebo, 16.0% reached it (23 of 143).
Most people stuck with it. Of the 567 volunteers, 514 (90.7%) finished the full 48 weeks of treatment.
What about side effects?
The most common side effects were stomach and gut problems. They showed up in 47.9% of people on the 2 mg dose, 58.2% on 4 mg and 63.1% on 6 mg. In the placebo group it was 23.1%. Most cases were mild to moderate. Only 0.7% of participants stopped treatment for good because of side effects.
This is the same pattern doctors have seen with other medicines in this family. Stomach upset is the main thing to expect.
What is a GLP-1 drug, in plain words?
After you eat, your gut releases signals that tell your brain you are getting full. GLP-1 is one of those signals. Medicines built to copy it can make you feel full sooner and stay full longer. Ribupatide copies GLP-1 and also GIP, a second gut signal, which is why it is called a dual agonist.
What you can do today
Get your starting numbers so you are ready for any weight conversation. Go to the CDC adult BMI calculator, enter your height and weight, and write the result on a sticky note next to one question you want to ask at your next checkup.
For clinicians and researchers
Design: Multicenter, randomized, double-blind, placebo-controlled phase 3 trial at 55 sites in China; 567 adults without diabetes with overweight or obesity (mean age 34.4 years, 54.5% female). Once-weekly subcutaneous ribupatide 2, 4 or 6 mg vs placebo for 48 weeks.
Main result: Placebo-adjusted change in body weight at week 48 was -9.3 (95% CI, -11.4 to -7.3) percentage points with 2 mg, -15.0 (95% CI, -17.1 to -12.9) with 4 mg and -16.3 (95% CI, -18.4 to -14.2) with 6 mg (P < .001 for all).
Main limitation: Participants were adults in China without diabetes, with a mean age of 34.4 years, which limits generalizability; the abstract reports only 48 weeks of treatment, and gastrointestinal events were more frequent with ribupatide.
Open question: Whether weight loss is maintained beyond 48 weeks, and whether results hold in older adults, in people with diabetes and in other populations, remains to be tested.
Trial registry: NCT06396429
Talk about it at home
After you eat, your tummy and gut send a message up to your brain that says I’m full, a bit like the fuel gauge in a car telling the driver the tank is getting full. Scientists studied a helper that copies that message so the brain hears it more clearly. To keep things fair, chance decided who got the real helper and who got a look-alike, and nobody knew which was which until the end.
At dinner tonight, try putting your fork down between bites, then tell everyone at the table when you first noticed your tummy saying it was full, and compare notes to see if it happened at the same moment for everybody.
Try it at home
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Cite this article
Mongevity Desk. GLP-1 drugs: a new weekly shot cut body weight by about 18% in a trial. Mongevity. Published November 21, 2026. Accessed November 22, 2026. https://mongevity.science/metabolism/2026/11/glp-1-drugs-ribupatide-weekly-shot-weight-loss-trial/Mongevity Desk. GLP-1 drugs: a new weekly shot cut body weight by about 18% in a trial [Internet]. Mongevity; 2026 Nov 21 cited 2026 Nov 22]. Available from: https://mongevity.science/metabolism/2026/11/glp-1-drugs-ribupatide-weekly-shot-weight-loss-trial/Mongevity Desk. (2026, November 21). GLP-1 drugs: a new weekly shot cut body weight by about 18% in a trial. Mongevity. https://mongevity.science/metabolism/2026/11/glp-1-drugs-ribupatide-weekly-shot-weight-loss-trial/
<a href="https://mongevity.science/metabolism/2026/11/glp-1-drugs-ribupatide-weekly-shot-weight-loss-trial/">GLP-1 drugs: a new weekly shot cut body weight by about 18% in a trial</a>
Free to share or quote with credit and a link.
Questions and answers
- How much weight did people lose with ribupatide?
- After 48 weeks, people lost an average of 10.7%, 16.4% or 17.7% of their body weight on the 2 mg, 4 mg and 6 mg doses. People on placebo lost 1.4%.
- Who was in the trial?
- The trial enrolled 567 adults in China with overweight or obesity and no diabetes. Their average age was 34.4.
- What were the side effects?
- Stomach and gut problems were the most common, affecting 47.9% to 63.1% of people on the medicine versus 23.1% on placebo. Most were mild to moderate.
- How is ribupatide different from other GLP-1 drugs?
- It is a dual agonist, which means it acts on both GLP-1 and GIP, two gut signals tied to fullness. It is given as a once-weekly shot under the skin.





